套细胞淋巴瘤-话题@MedSci

#套细胞淋巴瘤#

9篇内容 | 2495人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2117709, encodeId=6605211e70902, content=<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a><a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>, objectTitle=《套细胞淋巴瘤诊断与治疗中国指南（2022年版）》解读, objectType=guider, longId=21937, objectId=7bf1f1c002929810, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=7bf1f1c002929810, replyNumber=0, likeNumber=118, createdTime=2023-03-05, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7bf1f1c002929810, moduleTitle=《套细胞淋巴瘤诊断与治疗中国指南（2022年版）》解读, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=7bf1f1c002929810)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2111785, encodeId=55a72111e854f, content=<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a>加速批准非共价<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a><a href='/topic/show?id=4449105134e3' target=_blank style='color:#2F92EE;'>#pirtobrutinib#</a>上市，用于复发或难治性<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a></a>，相信适应症会快速扩展。百悦泽（<a href='/topic/show?id=2c90650e5b1' target=_blank style='color:#2F92EE;'>#泽布替尼#</a>）适应症包括既往至少接受过一种治疗的<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a></a>（MCL）、<a href='/topic/show?id=bde45355068' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞白血病#</a>/<a href='/topic/show?id=b0694e05245' target=_blank style='color:#2F92EE;'>#小淋巴细胞淋巴瘤#</a>（CLL/SLL）和<a href='/topic/show?id=391935910a2' target=_blank style='color:#2F92EE;'>#华氏巨球蛋白血症#</a>（WM）成人患者。, objectTitle=FDA加速批准非共价BTK抑制剂pirtobrutinib上市，用于复发或难治性套细胞淋巴瘤, objectType=article, longId=757311, objectId=4389e57311db, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230111/95519c54e03e45a6a91941d7963d6271.jpg, objectUrl=/article/show_article.do?id=4389e57311db, replyNumber=0, likeNumber=162, createdTime=2023-01-28, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4389e57311db, moduleTitle=FDA加速批准非共价BTK抑制剂pirtobrutinib上市，用于复发或难治性套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4389e57311db)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1242688, encodeId=08411242688ca, content=<a href='/topic/show?id=2c90650e5b1' target=_blank style='color:#2F92EE;'>#泽布替尼#</a>治疗复发/难治性<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a>, objectTitle=Blood：泽布替尼治疗复发/难治性套细胞淋巴瘤的长期疗效, objectType=article, longId=301380, objectId=19cc301380e9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022321/1647874982825_2467676.JPG, objectUrl=/article/show_article.do?id=19cc301380e9, replyNumber=0, likeNumber=109, createdTime=2022-09-02, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19cc301380e9, moduleTitle=Blood：泽布替尼治疗复发/难治性套细胞淋巴瘤的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19cc301380e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1220361, encodeId=7ff71220361e4, content=<a href='/topic/show?id=5be526941ee' target=_blank style='color:#2F92EE;'>#依鲁替尼#</a>联合<a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a>一线治疗<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a>, objectTitle=J Clin Oncol：依鲁替尼联合利妥昔单抗一线治疗套细胞淋巴瘤老年患者的疗效, objectType=article, longId=221135, objectId=393f22113570, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20211126/1637929373926_2110107.JPG, objectUrl=/article/show_article.do?id=393f22113570, replyNumber=0, likeNumber=166, createdTime=2022-05-17, rootId=0, userName=赛华佗, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=393f22113570, moduleTitle=J Clin Oncol：依鲁替尼联合利妥昔单抗一线治疗套细胞淋巴瘤老年患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=393f22113570)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1201329, encodeId=12db120132960, content=<a href='/topic/show?id=5be526941ee' target=_blank style='color:#2F92EE;'>#依鲁替尼#</a>-<a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a>诱导治疗可减少<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a>的化疗疗程, objectTitle=Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程, objectType=article, longId=295064, objectId=3d5529506462, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202222/1643796790052_5552845.jpg, objectUrl=/article/show_article.do?id=3d5529506462, replyNumber=0, likeNumber=163, createdTime=2022-03-10, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d5529506462, moduleTitle=Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d5529506462)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=918820, encodeId=0e08918820a3, content=<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a>, objectTitle=Lancet Haematol：3期| 套细胞淋巴瘤自体造血干细胞移植后采用来那度胺维持治疗, objectType=article, longId=206002, objectId=eebf206002c2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/147963-medical-pills-capsules.jpg, objectUrl=/article/show_article.do?id=eebf206002c2, replyNumber=0, likeNumber=142, createdTime=2021-01-21, rootId=0, userName=zb1235672, userId=59321624668, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eebf206002c2, moduleTitle=Lancet Haematol：3期| 套细胞淋巴瘤自体造血干细胞移植后采用来那度胺维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eebf206002c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=904215, encodeId=fede9042159b, content=<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a>还是相当罕见的, objectTitle=Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤, objectType=article, longId=204048, objectId=2fa5204048fb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020122/1606877914487_2110107.PNG, objectUrl=/article/show_article.do?id=2fa5204048fb, replyNumber=0, likeNumber=108, createdTime=2020-12-02, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fa5204048fb, moduleTitle=Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fa5204048fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

套细胞淋巴瘤

2020-05-29

lifestar (审核中...)

前往app查看评论内容

#套细胞淋巴瘤##淋巴瘤#

《套细胞淋巴瘤诊断与治疗中国指南（2022年版）》解读

2023-03-05发表于上海

lifestar (审核中...)

前往app查看评论内容

全文收起 #FDA#加速批准非共价#BTK抑制剂##pirtobrutinib#上市，用于复发或难治性 #套细胞淋巴瘤#，相信适应症会快速扩展。百悦泽（#泽布替尼#）适应症包括既往至少接受过一种治疗的 #套细胞淋巴瘤#（MCL）、#慢性淋巴细胞白血病#/#小淋巴细胞淋巴瘤#（CLL/SLL）和#华氏巨球蛋白血症#（WM）成人患者。

FDA加速批准非共价BTK抑制剂pirtobrutinib上市，用于复发或难治性套细胞淋巴瘤

2023-01-28发表于上海

小小医者 (审核中...)

前往app查看评论内容

#泽布替尼#治疗复发/难治性#套细胞淋巴瘤#

Blood：泽布替尼治疗复发/难治性套细胞淋巴瘤的长期疗效

2022-09-02

赛华佗 (审核中...)

前往app查看评论内容

#依鲁替尼#联合#利妥昔单抗#一线治疗#套细胞淋巴瘤#

J Clin Oncol：依鲁替尼联合利妥昔单抗一线治疗套细胞淋巴瘤老年患者的疗效

2022-05-17

医者仁者 (审核中...)

前往app查看评论内容

#依鲁替尼#-#利妥昔单抗#诱导治疗可减少#套细胞淋巴瘤#的化疗疗程

Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程

2022-03-10

zb1235672 (审核中...)

前往app查看评论内容

#套细胞淋巴瘤#

Lancet Haematol：3期| 套细胞淋巴瘤自体造血干细胞移植后采用来那度胺维持治疗

2021-01-21

lovetcm (审核中...)

前往app查看评论内容

#套细胞淋巴瘤#还是相当罕见的

Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤

2020-12-02

科室
- - 订阅+
  - 更多科室
工具
服务